Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Amortizatization of Intangibles: 2011-2025

Historic Amortizatization of Intangibles for Iovance Biotherapeutics (IOVA) over the last 5 years, with Sep 2025 value amounting to $5.8 million.

  • Iovance Biotherapeutics' Amortizatization of Intangibles rose 5.45% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.4 million, marking a year-over-year increase of 21.20%. This contributed to the annual value of $21.2 million for FY2024, which is 81.06% up from last year.
  • According to the latest figures from Q3 2025, Iovance Biotherapeutics' Amortizatization of Intangibles is $5.8 million, which was up 1.75% from $5.7 million recorded in Q2 2025.
  • Iovance Biotherapeutics' Amortizatization of Intangibles' 5-year high stood at $5.8 million during Q3 2025, with a 5-year trough of $1.9 million in Q2 2023.
  • Over the past 3 years, Iovance Biotherapeutics' median Amortizatization of Intangibles value was $5.4 million (recorded in 2025), while the average stood at $4.5 million.
  • Data for Iovance Biotherapeutics' Amortizatization of Intangibles shows a peak YoY spiked of 189.47% (in 2024) over the last 5 years.
  • Over the past 3 years, Iovance Biotherapeutics' Amortizatization of Intangibles (Quarterly) stood at $2.9 million in 2023, then spiked by 92.71% to $5.5 million in 2024, then climbed by 5.45% to $5.8 million in 2025.
  • Its last three reported values are $5.8 million in Q3 2025, $5.7 million for Q2 2025, and $5.4 million during Q1 2025.